Ulcerative Colitis Therapeutics Pipeline Analysis 2017 — Clinical Trials & Results, and Other Developments
The ulcerative colitis pipeline analysis report covers approximately 89 drug candidates, of which 68 drug candidates are in active stage. Among the active drug candidates, one drug is in NDA filed stage, 11 are in Phase III stage, 28 are in Phase II stage, 13 are in Phase I stage, 14 are in Pre-Clinical stage and one drug is in Discovery stage of development. The development of 18 ulcerative colitis drug candidates is found to be inactive and three drug candidates are discontinued.
Ulcerative colitis is a chronic inflammatory disease, which basically affect colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. The treatment approaches to this disease mostly include the use of small molecules and monoclonal antibodies, which are being developed to target and reduce the inflammatory mediators. The treatment of ulcerative colitis includes tumor necrosis factor inhibitors, such as adalimumab, golimumab and infliximab.
Browse Detailed Report Description at: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis
Pipeline Insights
The pipeline for ulcerative colitis was analyzed based on route of administration, molecule type and phase of drugs. Based on route of administration, around 46.0% of the active pipeline drug candidates of ulcerative colitis are being developed to be administered by oral route and 29.0% by are being developed to be administered by intravenous and subcutaneous route. Approximately 3.0% drug candidate are being administered by parenteral route, and 4.0% drug candidates are administered by intravenous; subcutaneous route. The route of administration of 29.0% drug candidates is undisclosed. The route of administration of 18.0% drug candidates are being administered by intravenous infusion, rectal, topical and others.
Several pharmaceutical companies engaged in the development of the ulcerative colitis drug candidates include, but are not limited to, Novartis Pharmaceuticals, EA Pharma Co., Ltd., Celgene Corporation, Galapagos NV, Lipid Therapeutics GmbH, and Momenta Pharmaceuticals, Inc.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis/report-sample
Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB, F. Hoffman-La Roche AG, Sigmoid Pharma Ltd., Pfizer, Inc., Momenta Pharmaceuticals, Inc., Johnson & Johnson, Arena Pharmaceuticals, Inc., and Novartis AG.
